Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Receives FDA IND Clearance, Joining MindRank’s First-in-Class Oncology Pipeline – EastMud

Dual WEE1/YES1 Kinase Inhibitor MRANK-106 Secures FDA IND Clearance, Positioning MindRank in First-in-Class Oncology Pipeline - Pipelinereview

HANGZHOU, China and LONDON, UK I March 07, 2025 I MindRank, a clinical stage artificial intelligence (AI)-empowered drug discovery company, announces today that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for MRANK-106, a first-in-class, orally available dual inhibitor of WEE1 and YES1 kinases, for the treatment of pancreatic cancer, small cell lung cancer, ovarian cancer, brea…

FDA Clears Phase 1 Trial of MRANK-106 in Advanced Solid Tumors

The FDA cleared the investigational new drug application for MRANK-106, a dual WEE1/YES1 kinase inhibitor, targeting advanced solid tumors.

(SeaPRwire) – Hangzhou, China and London, March 07, 2025 — MindRank, a clinical-stage artificial intelligence (AI)-enabled drug discovery company, today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s IND (Investigational New Drug) application for MRANK-106. MRANK-106 is a first-in-class, orally active dual inhibitor of WEE1 and YES1 kinases for the treatment of pancreatic cancer, small cell lung cancer, ova…